Kamada (NASDAQ:KMDA) Stock Price Passes Below 50 Day Moving Average – Should You Sell?

Kamada Ltd. (NASDAQ:KMDA) shares crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $7.66 and traded as low as $7.30. Kamada shares last traded at $7.31, with a volume of 35,012 shares changing hands.

Wall Street Analysts Forecast Growth

KMDA has been the subject of a number of recent analyst reports. Weiss Ratings lowered Kamada from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, June 25th. Stifel Nicolaus set a $11.00 price target on Kamada in a research note on Wednesday, March 11th. Benchmark reissued a “buy” rating on shares of Kamada in a research report on Thursday, March 12th. Finally, Wall Street Zen cut shares of Kamada from a “buy” rating to a “hold” rating in a research note on Saturday, May 23rd. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $12.00.

Kamada Stock Down 2.4%

The stock has a market cap of $420.40 million, a P/E ratio of 20.89, a P/E/G ratio of 0.69 and a beta of 0.85. The firm has a 50 day moving average price of $7.66 and a 200 day moving average price of $8.04.

Kamada (NASDAQ:KMDA) last announced its quarterly earnings data on Thursday, May 14th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.05). The company had revenue of $45.24 million for the quarter, compared to the consensus estimate of $46.72 million. Kamada had a net margin of 11.21% and a return on equity of 7.73%. Equities analysts predict that Kamada Ltd. will post 0.44 earnings per share for the current fiscal year.

Institutional Trading of Kamada

A number of hedge funds and other institutional investors have recently modified their holdings of KMDA. Y.D. More Investments Ltd lifted its stake in shares of Kamada by 7.3% during the 4th quarter. Y.D. More Investments Ltd now owns 289,382 shares of the biotechnology company’s stock valued at $2,050,000 after buying an additional 19,717 shares in the last quarter. Marshall Wace LLP increased its stake in Kamada by 25.9% in the 4th quarter. Marshall Wace LLP now owns 196,954 shares of the biotechnology company’s stock worth $1,390,000 after buying an additional 40,514 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Kamada by 43.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 167,521 shares of the biotechnology company’s stock worth $1,183,000 after buying an additional 50,608 shares in the last quarter. Huntleigh Advisors Inc. raised its holdings in Kamada by 5.5% during the fourth quarter. Huntleigh Advisors Inc. now owns 149,374 shares of the biotechnology company’s stock valued at $1,055,000 after acquiring an additional 7,812 shares during the period. Finally, Two Sigma Investments LP raised its holdings in Kamada by 4.3% during the third quarter. Two Sigma Investments LP now owns 109,589 shares of the biotechnology company’s stock valued at $761,000 after acquiring an additional 4,504 shares during the period. 20.38% of the stock is owned by hedge funds and other institutional investors.

About Kamada

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.